Department

Neurology

TBI, Stroke, Dementia, Cognitive Enhancement

0 FDA-approved 7 research

HBOT Applications

Investigational / Preclinical Level B

Mild Traumatic Brain Injury (mTBI)

B-level evidence from clinical trials demonstrating improvements in neurocognitive deficits, post-concussion symptoms, and brain microstructure in mTBI patients.

Protocol

Pressure

1.5 – 2.0 ATA

Duration

60 – 90 min

Sessions

40 – 60

Frequency

Once daily, 5×/week

Evidence basis: Level B Evidence

References: 15
Investigational / Preclinical Level B

Stroke Recovery

Investigational adjunctive therapy for ischemic stroke recovery. HBOT promotes neuroplasticity, reduces peri-infarct hypoxia, and may improve functional outcomes.

Protocol

Pressure

2.0 ATA

Duration

90 min

Sessions

40 – 60

Frequency

Once daily, 5×/week

Evidence basis: Clinical Research

References: 16
Investigational / Preclinical Level B

Vascular Dementia

HBOT reverses chronic cerebral hypoperfusion and promotes angiogenesis in brain tissue. Clinical studies show improvements in cognitive function in vascular dementia patients.

Protocol

Pressure

2.0 ATA

Duration

90 min

Sessions

60

Frequency

Once daily, 5×/week

Evidence basis: Clinical Research

References: 16
Investigational / Preclinical Level A (RCT)

Cognitive Enhancement in Healthy Aging

Randomized controlled trial demonstrated significant cognitive enhancements in healthy older adults, including memory and processing speed improvements correlated with increased cerebral blood flow.

Protocol

Pressure

2.0 ATA

Duration

90 min

Sessions

60

Frequency

Once daily, 5×/week

Evidence basis: RCT (Hadanny et al., 2020)

References: 4
Investigational / Preclinical Level C

Neurodegenerative Diseases

Emerging preclinical and early clinical evidence for Alzheimer's disease and Parkinson's disease. HBOT reduces neuroinflammation and promotes neurogenesis.

Protocol

Pressure

2.0 ATA

Duration

90 min

Sessions

40 – 60

Frequency

Once daily, 5×/week

Evidence basis: Preclinical / Early Phase

References: 8
Emerging Evidence Level B

Long COVID

Persistent cognitive dysfunction, brain fog, fatigue, sleep disturbance, and pain following SARS-CoV-2 infection. A randomised controlled trial reported significant improvements after 40 HBOT sessions, with benefits sustained at one-year follow-up. Evidence currently anchored to a single research group; independent replication ongoing.

Protocol

Pressure

2.0 ATA

Duration

90 min

Sessions

40

Frequency

5×/week

Evidence basis: RCT (Zilberman-Itskovich et al., 2022)

Emerging Evidence Level B

Fibromyalgia

Chronic central sensitisation syndrome with widespread pain, tender points, fatigue, sleep disturbance, and cognitive symptoms. A 2015 prospective controlled trial reported significant improvements after 40 HBOT sessions at 2.0 ATA, with two independent 2023 meta-analyses confirming improvements in function, tender points, fatigue, sleep, and quality of life across pooled randomised data.

Protocol

Pressure

2.0 ATA

Duration

90 min

Sessions

40

Frequency

5×/week

Evidence basis: Prospective Controlled Trial (Efrati et al., 2015)